Ablynx.com / Board of Directors

Three-dimensional structure of a Nanobody^®(modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Home

ABOUT ABLYNX

Board of directors > Steven Bunting

Board of Directors

Stephen Bunting, Abingworth Management

Stephen Bunting has more than 20 years experience of life science venture capital investment. He joined Abingworth in 1987 and became its Managing Director in 2002. He has been a Director of a number of companies in the US and Europe and was Founding Chairman of Astex Therapeutics, Devgen and Hexagen. Other directorships have included Aurora Biosciences, Cantab Pharmaceuticals and Genetic Therapy. Before joining Abingworth, he worked for N M Rothschild & Sons who were advisers to Biotechnology Investments Limited. At Abingworth he is responsible for building and leading the team and for investment strategy. He is active in UK and Continental European deals. Stephen has a PhD in Biological Sciences.